Yarrow Bioscience, Inc. — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 2/100
What the filing says
Rebecca Frey (CEO) and Tyler Zeronda (CFO) certified the Q2 2026 10-Q (quarter ended June 30, 2026) filed August 13, 2026. Standard SOX 302/906 certifications confirm financial statements fairly present the company's condition and operations, and that disclosure controls and internal controls are effective. No material changes, deficiencies, or fraud were disclosed.
Why this rating
Routine periodic SEC certifications; standard boilerplate disclosure required for all public companies. No transactions, operational changes, or control issues disclosed.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.